This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-05. Anything still debated is marked as such rather than presented as settled.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
=== Legal status === The US Food and Drug Administration (FDA) granted the application for dupilumab priority review designation and in March 2017, the FDA approved dupilumab injection to treat adults with moderate-to-severe eczema. The FDA granted the application breakthrough therapy designation.
== Function and expression == Grb2 is widely expressed and is essential for multiple cellular functions. Inhibition of Grb2 function impairs developmental processes in various organisms and blocks transformation and proliferation of various cell types. It is thus not surprising that targeted gene disruption of Grb2 in mice is lethal at an early embryonic stage. Grb2 is best known for its ability to link the epidermal growth factor receptor tyrosine kinase to the activation of Ras and its downstream kinases, ERK1,2. Grb2 is composed of an SH2 domain flanked on each side by an SH3 domain. Grb2 has two closely related proteins with similar domain organizations, Gads and Grap. Gads and Grap are expressed specifically in hematopoietic cells and function in the coordination of tyrosine kinase mediated signal transduction.
=== Reconstitution === On 13 August 1976, Deputy Premier and Liberal leader Sir Gordon Chalk resigned, resulting in a reshuffle. William Knox replaced Chalk in his roles, while John Greenwood was appointed to the vacant position in the ministry. Keith Hooper, Minister for Transport and Liberal member for Greenslopes, died on 23 August 1977. Fred Campbell added Transport to his roles for the remainder of the parliamentary term.
Sonic Corporation, founded as Sonic Drive-In and more commonly known as Sonic (stylized in all caps), is an American drive-in fast-food chain owned by Inspire Brands, the parent company of Arby's, Jimmy John's, Buffalo Wild Wings, Baskin-Robbins, and Dunkin'. Sonic, founded by Troy N. Smith Sr., opened its first location in 1953, under the name Top Hat Drive-In. Originally a walk-up root beer stand outside a log-cabin steakhouse selling soda, hamburgers, and hot dogs, Sonic expanded to over 3,400 locations in the United States. Sonic is known for its use of carhops on roller skates, and hosts an annual competition in most locations to determine the top skating carhop in the company. The company's core products include the "Chili Cheese Coney", "Sonic Cheeseburger Combo", "Sonic Blasts", "Master Shakes", and "Wacky Pack Kids Meals".
Sources: en.wikipedia.org
However, it is possible that some isotopes that are now considered stable will be revealed to decay with extremely long half-lives (as happened with bismuth). For each of the 80 stable elements, the number of stable isotopes is given. Only 90 isotopes are stable against any possible decay, and an additional 161 are energetically unstable (see List of nuclides) but have never been observed to decay. Thus, 251 isotopes (nuclides) are stable by definition (including an excited state, tantalum-180m, for which no decay has yet been observed). In April 2019 it was announced that the half-life of xenon-124 had been measured to 1.8 × 1022 years. This is the longest half-life directly measured for any unstable isotope; only the (indirectly measured) half-life of tellurium-128 is longer. Of the chemical elements, only 1 element (tin) has 10 such stable isotopes, 5 have 7 stable isotopes, 7 have 6 stable isotopes, 11 have 5 stable isotopes, 9 have 4 stable isotopes, 5 have 3 stable isotopes, 16 have 2 stable isotopes, and 26 have 1 stable isotope. Additionally, 31 nuclides of the naturally occurring elements have unstable isotopes with a half-life long enough to have survived for the age of the Solar System (108 years or more), and an additional four such nuclides represent three elements (bismuth, thorium, uranium) having no stable isotope. These 35 radioactive naturally occurring nuclides comprise the radioactive primordial nuclides. The total number of primordial nuclides is then 251 (the stable nuclides) plus the 35 radioactive primordial nuclides, for a total of 286.
== Function == Following binding of GnRH, the GnRHR associates with G-proteins that activate a phosphatidylinositol (PtdIns)-calcium second messenger system. Activation of the GnRHR ultimately causes the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH).
German is auxiliary, but a lack of Polish-speaking officials means German is still used in the judiciary until 1920. 25 May 1919: The Army of Great Poland is subjugated to the headquarters of the Polish Army but keeps its separate organisation. 30 May 1919: The People's Guard is transformed to the Home Defence (Obrona Krajowa). 1 June 1919: By-elections of MPs to Sejm Ustawodawczy. 6 June 1919 Skirmishes near Bydgoszcz (Bromberg). The rising threat of a German offensive induces the Commission of the NRL to introduce a state of emergency in all lands under its jurisdiction. In a belt of 20 km from the front line, it introduces martial law. A few days later, the NRL announces capital punishment for acting against the Great Polish Army or for the German army. 18 June 1919: Skirmishes near Rynarzewo. 28 June 1919: The Treaty of Versailles gives almost all of Greater Poland to Poland. 1 July 1919 The Commission of the NRL removes customs border with ex-Kingdom of Poland. Artillery fire at front. 9 July 1919: Farther than 20 km from the front, end of state of emergency. 10 July 1919: Proceedings of the Polish government with Commission of the NRL on further policy in the former Prussian Partition (Były Zabór Pruski). Creation of the Ministry of the Former Prussian Partition (Ministerstwo Byłej Dzielnicy Pruskiej).
== Adverse effects == Besides being a hepatocarcinogen, safrole exhibits further adverse effects in that it will induce the formation of hepatic lipid hydroperoxides. Safrole also inhibits the defensive function of neutrophils against bacteria. In addition to the inhibition of the defensive function of neutrophils, it has also been discovered that safrole interferes with the formation of superoxides by neutrophils. Furthermore, safrole oxide, a metabolite of safrole, has a negative effect on the central nervous system. Safrole oxide inhibits the expression of integrin β4/SOD, leading to apoptosis of the nerve cells.
Ticket prices for the 2026 FIFA World Cup initially ranged from $60 for group stage matches to $6,730 for the final—an increase from the USD equivalent of $69 to $1,607 for the 2022 World Cup. However, in September 2025, FIFA confirmed it would use dynamic pricing for tickets for the first time, following the practice used in the 2025 FIFA Club World Cup. Special "hospitality" seats were made available in April 2025. An initial draw period for non-hospitality seats occurred between September 10–19, 2025, limited to Visa cardholders. A second phase ran from October 27–31, 2025, and a third phase started after the final draw of teams on December 5. Sales were capped at four tickets per person per match, and no person was able to purchase more than 40 tickets for the overall tournament. FIFA's official resale platform went live on October 2, 2025. A final "last-minute" sales phase reopened on April 22, 2026, approximately 50 days before the start of the tournament, with tickets for all 104 matches made available on a first-come, first-served basis. By that stage, more than five million tickets had been sold from an expected total exceeding six million, with additional tickets scheduled to be released in phases up to the final, subject to availability. Every city hosting the World Cup in the United States passed a law stating that ticket sales to World Cup events were exempt from state and local sales taxes.
Sources: en.wikipedia.org
== Umami taste == On a molecular level, the umami taste is registered when molecules such as glutamate and aspartate bind to the ligand-binding domains of specialized taste receptors. Once activated, these receptors send electrical pulses that travel to the brain via sensory neurons. In 1989, Tamura et al. found that, by themselves, basic residues such as Lys-Gly and Lys-Lys produced sour and salty tastes in their dihydrochloride forms while acidic residues such as Asp-Glu-Glu and Lys-Gly produced sour and sweet tastes. However, the umami taste is produced by combinations of acidic and basic amino acid residues, such as Lys-Gly-Asp. More specifically, the umami taste found in BMP is generated by the combination of lysine at the N-terminus and the acidic amino acids (Asp-Glu-Glu) in the midsection of the peptide, which suggests that cations and anions play a role in the stimulation of taste receptors to produce the umami taste. However, other factors beyond the presence of certain amino acids can affect the taste response of the peptide. The intensity of the umami taste increases when the acidic peptide interacts with cations to form a salt. At a threshold value of 1.25 millimolar (mM), the Asp-Glu dipeptide generates the strongest umami taste when exposed to NaOH and subjected to a pH increase. Position of the amino acids also play a role in taste intensity, as a Glu-Asp dipeptide registers at a threshold value of 3.14 mM, meaning it would need a higher amount of the compound in order for a person to register the umami taste.
Researchers and surgeons have conducted clinical and basic science studies to uncover the regenerative capacity possessed by the large animal species involved (humans and quadrupeds) for potential therapies to treat the disease. Some therapies, carried out by research laboratories in New York, include introduction of biologically engineered, injectable riboflavin cross-linked high density collagen (HDC-laden) gels into disease spinal segments to induce regeneration, ultimately restoring functionality and structure to the two main inner and outer components of vertebral discs—anulus fibrosus and the nucleus pulposus. A 2025 phase I clinical trial reported that intradiscal injection of autologous nucleus pulposus cells combined with endoscopic discectomy was safe in patients with chronic low back pain, with no serious adverse events over 24 months. The study also observed sustained improvements in pain, disability scores, and magnetic resonance imaging indicators of disc hydration and morphology.
=== Antihistamine === Cidoxepin is under development by Elorac, Inc. for the treatment of chronic urticaria (hives). As of 2017, it is in phase II clinical trials for this indication. The drug was also under investigation for the treatment of allergic rhinitis, atopic dermatitis, and contact dermatitis, but development for these indications was discontinued.
== Side effects == Common side effects are diarrhoea (in 5% of people receiving ertapenem), nausea (in 3%) and vomiting, reactions at the injection site (5%, including pain and inflammation of the vein), and headache. Uncommon but possibly serious side effects include candida infections, seizures, skin reactions such as rashes (including nappy rash in children), and anaphylaxis. Hypersensitivity cross-reactions with penicillins are rare. Ertapenem also can have an effect on some blood tests such as liver enzymes and platelet count.
=== Privacy and independence === A Nature editorial suggests medical care could become dependent on AI models that could be taken down at any time, are difficult to evaluate, and may threaten patient privacy. Its authors propose that health-care institutions, academic researchers, clinicians, patients and technology companies worldwide should collaborate to build open-source models for health care of which the underlying code and base models are easily accessible and can be fine-tuned freely with own data sets.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.